Igea D'Agnano

Dr. Igea D'Agnano

CNR-Institute for Biomedical Technologies, Italy
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2000 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
DGDaniele Guardavaccaro
Daniele Guardavaccaro
GCGiuseppina Corrente
Giuseppina Corrente
FCFrancesca Covone
Francesca Covone
LMLaura Micheli
Laura Micheli
Igea D'AgnanoIgea D'Agnano
Igea D'Agnano
FTFelice Tirone
Felice Tirone
The p53-inducible gene PC3 (TIS21, BTG2) is endowed with antiproliferative activity. Here we report that expression ofPC3 in cycling cells induced accumulation of hypophosphorylated, growth-inhibitory forms of pRb and led to G1 arrest. This latter was not observed in cells with genetic disruption of the Rb gene, indicating that thePC3-mediated G1 arrest was Rb dependent. Furthermore, (i) the arrest of G1-S transition exerted by PC3 was completely rescued by coexpression of cyclin D1 but not by that of cyclin A or E; (ii) expression of PC3 caused a significant down-regulation of cyclin D1 protein levels, also in Rb-defective cells, accompanied by inhibition of CDK4 activity in vivo; and (iii) the removal from the PC3 molecule of residues 50 to 68, a conserved domain of the PC3/BTG/Tob gene family, which we term GR, led to a loss of the inhibition of proliferation as well as of the down-regulation of cyclin D1 levels. These data point to cyclin D1 down-regulation as the main factor responsible for the growth inhibition by PC3. Such an effect was associated with a decrease of cyclin D1 transcript and of cyclin D1 promoter activity, whereas no effect of PC3 was observed on cyclin D1 protein stability. Taken together, these findings indicate that PC3 impairs G1-S transition by inhibiting pRb function in consequence of a reduction of cyclin D1 levels and that PC3 acts, either directly or indirectly, as a transcriptional regulator of cyclin D1.

1 December 2012 in Toxicology in Vitro
Verified
Journal Article
Closed access
MNManuela Natoli
Manuela Natoli
BLBruno Daniele Leoni
Bruno Daniele Leoni
Igea D'AgnanoIgea D'Agnano
Igea D'Agnano
FZFlavia Zucco
Flavia Zucco
AFArmando Felsani
Armando Felsani

2 April 2015 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GFGermana Falcone
Germana Falcone
AFArmando Felsani
Armando Felsani
Igea D'AgnanoIgea D'Agnano
Igea D'Agnano
A class of small non-coding RNAs, the microRNAs (miRNAs), have recently attracted great attention in cancer research since they play a central role in regulation of gene-expression and miRNA aberrant expression is found in almost all types of human cancer. The discovery of circulating miRNAs in body fluids and the finding that they are often tumor specific and can be detected early in tumorigenesis has soon led to the evaluation of their possible use as cancer biomarkers and treatment-response predictors. The evidence that tumor cells communicate via the secretion and delivery of miRNAs packed into tumor-released microvesicles has prompted to investigate miRNA contribution as signaling molecules to the establishment and maintenance of the tumor microenvironment and the metastatic niche in cancer. In this review we highlight the recent advances on the role of exosomal miRNAs as mediators of cancer cell-to-cell communication.

1 April 2001 in The American Journal of Pathology
Verified
Journal Article
Open access
PDF file
ABAnnamaria Biroccio
Annamaria Biroccio
BBBarbara Benassi
Barbara Benassi
Igea D'AgnanoIgea D'Agnano
Igea D'Agnano
CDCarmen D’angelo
Carmen D’angelo
SBSimonetta Buglioni
Simonetta Buglioni
GZGabriella Zupi
Gabriella Zupi
The aim of this study was twofold: to assess the relationship between c-Myb and Bcl-x expression and to evaluate the prognostic significance of their expression in colorectal carcinoma (CRC) patients. Analysis of tumors from 91 CRC patients for expression of c-Myb and Bcl-x revealed a significant relationship between these two proteins. Kaplan-Meier’s analysis showed an increased risk of relapse and death in patients whose tumor specimens displayed high c-Myb levels and Bcl-x positivity. Similar results were also observed excluding Dukes’ D patients. Molecular analysis using three c-Myb-overexpressing LoVo clones indicated that c-Myb overexpression was accompanied by up-regulation of Bcl-xL protein and mRNA. Tumors originating from these clones injected in nude mice were significantly larger than those formed in mice injected with parental or vector-transfected LoVo cells. Moreover, tumors derived from parental and control vector-transfected but not from c-Myb-overexpressing LoVo cells showed high frequency of apoptotic cells. These results provide direct evidence of an association between c-Myb and Bcl-x expression and suggest that expression of both molecules might be a useful prognostic marker in CRC.

21 June 2004 in Oncogene
Verified
Journal Article
Closed access
LALaura Asnaghi
Laura Asnaghi
ACAngela Calastretti
Angela Calastretti
ABAnnamaria Bevilacqua
Annamaria Bevilacqua
Igea D'AgnanoIgea D'Agnano
Igea D'Agnano
GGGiuliana Gatti
Giuliana Gatti
ANAngelo Nicolin
Angelo Nicolin

1 August 1992 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
GCG Citro
G Citro
DPD Perrotti
D Perrotti
CCC Cucco
C Cucco
Igea D'AgnanoIgea D'Agnano
Igea D'Agnano
ASA Sacchi
A Sacchi
BCB Calabretta
B Calabretta
Exposure of human leukemia HL-60 cells to an oligodeoxynucleotide complementary to an 18-base sequence (codons 2-7) of c-myb-encoded mRNA has previously been shown to result in inhibition of cell proliferation. Because HL-60 cells express high levels of transferrin receptor we adapted a DNA delivery system based on receptor-mediated endocytosis to introduce myb oligomers complexed with a transferrin-polylysine conjugate into those cells. A DNA.RNA duplex resistant to S1 nuclease digestion was detected as early as 12 hr after culture of HL-60 cells in the presence of the myb antisense/transferrin-polylysine complex. Exposure of HL-60 cells to the myb antisense/transferrin-polylysine complex resulted in rapid and profound inhibition of proliferation and loss of cell viability much more pronounced than that occurring in cells exposed to free myb antisense oligodeoxynucleotides. The transferrin-polylysine/myb sense complex or the transferrin-polylysine conjugate alone had no effect on HL-60 cell proliferation and viability. These findings indicate that myb synthetic oligodeoxynucleotides enter efficiently into HL-60 by transferrin receptor-mediated endocytosis and exert a profound biological effect. Such a delivery system could exploit other ligand-receptor interactions for the selective delivery of oncogene-targeted antisense oligodeoxynucleotides.